Blog
RSS FeedPosted by Michael Wonder on 15 Oct 2019
Wanted: better policies and incentives to revitalise R&D for new antimicrobial drugs
15 October 2019 - In the not-too-distant future that we could be facing — one with rampant, uncontrollable, multidrug-resistant microbes ...
Posted by Michael Wonder on 15 Oct 2019
Faced with a drug shortfall, doctors scramble to treat children with cancer
14 October 2019 - A critical chemotherapy medication is in short supply, and physicians say there is no appropriate substitute. ...
Posted by Michael Wonder on 15 Oct 2019
U.S. FDA approves Secuado (asenapine) transdermal system, the first-and-only transdermal patch for the treatment of adults with schizophrenia
15 October 2019 - Noven Pharmaceuticals today announced the U.S. FDA has approved Secuado (asenapine) transdermal system, the first-and-only transdermal patch ...
Posted by Michael Wonder on 15 Oct 2019
Patient experience data: researchers call for more consistency from FDA
14 October 2019 - Researchers at drug maker Sanofi are calling on the US FDA to make its publication of ...
Posted by Michael Wonder on 15 Oct 2019
Xenikos receives FDA fast track designation for T-Guard(R) for treating steroid-refractory acute graft-versus-host disease
14 October 2019 - Xenikos is currently preparing to initiate a U.S. pivotal Phase 3 trial. ...
Posted by Michael Wonder on 15 Oct 2019
Akorn receives FDA approval for betamethasone dipropionate 0.05% lotion USP (augmented)
14 October 2019 - Akorn today announced that it received a new abbreviated new drug application approval from the U.S. ...
Posted by Michael Wonder on 14 Oct 2019
Flexion Therapeutics announces extended FDA review of supplemental new drug application for Zilretta
14 October 2019 - Flexion Therapeutics today announced that the U.S. FDA has informed the company it needs additional time ...
Posted by Michael Wonder on 14 Oct 2019
FDA bid to bolster generic competition and combat shortages isn’t working — yet
14 October 2019 - Although the FDA has maintained that additional generic approvals should promote competition and alleviate shortages, the ...
Posted by Michael Wonder on 14 Oct 2019
FDA is smashing the status quo for regulatory science
14 October 2019 - A recent press release from the FDA titled “Reorganization of the Office of New Drugs with ...
Posted by Michael Wonder on 14 Oct 2019
U.S. FDA approves Xarelto (rivaroxaban) to help prevent blood clots in acutely ill medical patients
14 October 2019 - Xarelto provides a new oral option to help prevent venous thromboembolism (VTE) and VTE-related death during hospitalisation ...
Posted by Michael Wonder on 12 Oct 2019
Have FDA’s generic approvals helped with competition? Researchers say too early to tell
11 October 2019 - Amid increasing abbreviated new drug application approvals, efforts by the US FDA to promote generic drug development ...
Posted by Michael Wonder on 12 Oct 2019
FDA approves new treatment for patients with migraine
11 October 2019 - The U.S. FDA today approved Reyvow (lasmiditan) tablets for the acute (active but short-term) treatment of migraine ...
Posted by Michael Wonder on 11 Oct 2019
MSF demands Johnson & Johnson reduce price of life saving TB drug
11 October 2019 - Pharma company Johnson and Johnson sell TB drug bedaquiline for nearly US$1,200 per treatment course, a price ...
Posted by Michael Wonder on 11 Oct 2019
Pharma industry is 'right in the crosshairs,' Merck CEO Kenneth Frazier says
11 October 2019 - President Donald Trump and House Speaker Nancy Pelosi are in a battle over impeachment but their ...
Posted by Michael Wonder on 10 Oct 2019
FDA grants FX-322 fast track designation
10 October 2019 - The company also announced today that the U.S. FDA has granted fast track designation for FX-322. ...